Studies photodynamic therapy with surgery for glioblastoma brain tumors
Compares photodynamic therapy plus surgery with traditional treatment in adults with glioblastoma.
Plain-language title generated from the registry record
Registry title: Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence
Key facts
- Where
- Hangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with glioblastoma (GBM), a type of brain tumour, confirmed by pathology. It compares surgery with photodynamic therapy against surgery alone.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Pathologically confirmed primary focal GBM, recurrent GBM (single or satellite lesions), or multiple GBM (multiple germinal centers).
Main reasons for not taking part
- Allergy to the photosensitizer
- Severe blood clotting disorder
- Severe heart or brain blood vessel disease, especially in the acute stage
- Multiple organ failure or end-stage disease
- Pregnancy, or other brain tumour types, or not agreeing to informed consent
Read by machine on 9 November 2026.
Where in China
- Zhejiang Provincial People's HospitalHangzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zhejiang Provincial People's Hospital
- Trial code
- NCT06939400
- Record updated
- 22 April 2025
- Original description
GBM patients receiving PDT treatment (50 cases，surgery combined with photodynamic therapy) and traditional treatment (50 cases，traditional surgery) in our hospital and partner hospitals were collected. The prognosis was analyzed by comparing with the control group from multiple perspectives such as image evaluation, imaging effect, Karnofsky score, median survival time and survival rate.Read full original descriptionShow less
Study on Precision Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence
GBM patients receiving PDT treatment (50 cases，surgery combined with photodynamic therapy) and traditional treatment (50 cases，traditional surgery) in our hospital and partner hospitals were collected. The prognosis was analyzed by comparing with the control group from multiple perspectives such as image evaluation, imaging effect, Karnofsky score, median survival time and survival rate.
Inclusion: Pathologically confirmed primary focal GBM; Recurrent GBM(single or satellite lesions); Multiple (multiple germinal centers)GBM.
Exclusion: Photosensitizer allergy; Severe coagulation disorder; Patients with severe cardiovascular and cerebrovascular diseases, especially patients in the acute stage; Multiple organ failure, end-stage patients. ⑤ Pregnant women: Photofrin is considered a class C pregnancy risk (toxic, non-teratogenic) drug with non-dialysis properties; Non-gbm diagnosis: Patients with other types of brain tumors or diseases. 7 Do not agree to informed consent: patients who are unwilling to sign informed consent or do not agree to participate in the study.